46 results about "Human specific" patented technology

Collecting images of a patron in an entertainment venue is performed by facial recognition of the patron's face within the images, simplifying the storage and distribution of the images for a patron. In order to enhance the reliability of the facial recognition system, information about the patron that is not directly related to most facial recognition systems, including clothes, height, other associated people, use of glasses and jewelry, disposition of facial hair, and more, can be used. Some of the characteristics used can be specific to a particular date or event, and which will not be more generally characteristic of the patron. The facial recognition system can also be used to identify the patron requesting images to be collected. The present invention also relates to the use of facial recognition in sorting and collecting images from an electronically-stored image collection, enabling the easy retrieval of images that are related to a particular person or set of people.

A method and apparatus for video retrieval and cueing that automatically detects human faces in the video and identifies face-specific video frames so as to allow retrieval and viewing of person-specific video segments. In one embodiment, the method locates human faces in the video, stores the time stamps associated with each face, displays a single image associated with each face, matches each face against a database, computes face locations with respect to a common 3D coordinate system, and provides a means of displaying: 1) information retrieved from the database associated with a selected person or people, 2) path of travel associated with a selected person or people 3) interaction graph of people in video, 4) video segments associated with each person and / or face. The method may also provide the ability to input and store text annotations associated with each person, face, and video segment, and the ability to enroll and remove people from database. The videos of non-human objects may be processed in a similar manner. Because of the rules governing abstracts, this abstract should not be used to construe the claims.

Collecting images of a patron in an entertainment venue is performed by facial recognition of the patron's face within the images, simplifying the storage and distribution of the images for a patron. In order to enhance the reliability of the facial recognition system, information about the patron that is not directly related to most facial recognition systems, including clothes, height, other associated people, use of glasses and jewelry, disposition of facial hair, and more, can be used. Some of the characteristics used can be specific to a particular date or event, and which will not be more generally characteristic of the patron. The facial recognition system can also be used to identify the patron requesting images to be collected. The present invention also relates to the use of facial recognition in sorting and collecting images from an electronically-stored image collection, enabling the easy retrieval of images that are related to a particular person or set of people.

There is provided a method that includes (a) receiving first information about a patient via a first user interface that is communicatively coupled to a communication network, (b) receiving second information about the patient via a second user interface that is communicatively coupled to the communication network, where the first information and the second information, together, comprise answered questions, (c) evaluating the answered questions, to yield a suggested diagnosis and a follow-up question, and (d) transmitting the suggested diagnosis and the follow-up question to the second user interface via the communication network. There is also provided a system that employs the method, and a storage device that contains instructions that cause a processor to perform the method.

Systems and methods are provided for validating the authenticity of a signature on a document by providing a document from an account, the document including an actual signature and a machine-readable identifier, wherein the machine-readable identifier contains a string of data representing the integral characteristics of all valid account signatures and a person-specific confidence threshold. When the document is presented at a point of presentment, the document is scanned into a document-processing machine and the actual signature is compared against all valid account signatures.

Disclosed is a method for managing obesity, diabetes, hair loss, aging, cardiovascular, or other blood glucose-spike-induced diseases by reducing the post-prandial blood glucose spike, or the glucose shock. The blood glucose spike, or the glucose shock is reduced by generating a person-specific glucose profile for at least one significant meal to tune or train a blood glucose model (kinetic, artificial intelligence or hybrid), and then using the tuned or the trained model embedded in a computation-capable electronic device to compute and recommend a person-specific meal plan and an exercise plan, including semi-continuous meal ingestion and post-meal exercise while sitting at home or office. Advantages over prior art are that the method uses less strenuous exercise with no or less medicine, is person-specific, quantitative and more suitable for use by an individual, a dietician, or a health care practitioner.

Systems and methods are provided for validating the authenticity of a signature on a document by providing a document from an account, the document including an actual signature and a machine-readable identifier, wherein the machine-readable identifier contains a string of data representing the integral characteristics of all valid account signatures and a person-specific confidence threshold. When the document is presented at a point of presentment, the document is scanned into a document-processing machine and the actual signature is compared against all valid account signatures.

The invention relates to a PDL1 monoclonal antibody and application thereof and belongs to the technical field of immunology. A separated human specific binding molecule provided by the invention comprises a) and b), wherein a) three light-chain CDRs comprise a light-chain CDR1, a light-chain CDR2 and a light-chain CDR3; b) three heavy-chain CDRs comprise a heavy-chain CDR1, a heavy-chain CDR2 anda heavy-chain CDR3; the separated human PDL1 specific binding molecule is a separated antibody or antigen binding fragment. The PDL1 monoclonal antibody provided by the invention can be used for effectively inhibiting partial tumor growth; a PD1 / PDL1 signal is blocked so that the proliferation of tumor antigen specific T cells can be accelerated and the effect of killing tumor cells is realized;a related PDL1 signal on the tumor cells is blocked so that the secretion of an infiltrated CD8<+>T cell IFN-gamma can be up-regulated.

The invention discloses a distributed DTW (Dynamic Time Warping) human behaviour intention identification method based on human behaviour characteristics. The distributed DTW human behaviour intention identification method based on the human behaviour characteristics comprises the following steps of: obtaining human behaviour characteristics in a current frame, and adding the human behaviour characteristics in the current frame into a human behaviour characteristic time sequence; matching a currently observed human behaviour characteristic sequence with a learned specific behaviour sequence in a database template by utilizing a DTW algorithm, and calculating the best matching similarity of the two based on a chi-square distance; reversing the similarity, and performing normalization to obtain a matching probability; and, taking an action mode probability value of each sensor as consistency information amount, performing data exchange with an adjacent sensor again, and performing consistency iterative operation, so that identification results of adjacent sensor nodes are same finally. By means of the distributed DTW human behaviour intention identification method based on the human behaviour characteristics disclosed by the invention, precise human specific behaviour identification can be realized.

It is an object of the present invention to provide a transgenic non-human animal, which can appropriately evaluate properties, pharmacological effects and safety of a molecular targeted substance or targeted drug to a human specific molecule, and to provide a method for producing the transgenic non-human animal, which comprises a gene encoding a human specific molecule and a gene encoding a human Fcγ receptor family, both genes being introduced in the animal, thereby expressing the gene encoding a human specific molecule and the gene encoding a human Fcγ receptor family.

The invention relates to a method to select the cross reacting antigen by the computer auxiliary. It sets the protein data bank of the pathogeny microorganism and the human specific histiocyte, then to get the preset length of the similar subsequence by the local sequence comparing arithmetic; it sets the data bank of the linear epitope and the nonlinear epitope of the B cells to support the training of the SVM which predicts the probability of the linear epitope of the B cells. It selects the big probability of the similar subsequence according to the probability of the linear epitope of the B cells. The invention has decreased the experiment workload for the immunologist.

The invention discloses a test paper strip for detecting the concentration of thyroglobulin and a preparation method thereof. The test paper strip comprises strip-shaped nitrocellulose membranes arranged transversely and horizontally, and longitudinally spaced and parallel to each other on the cellulose acetate membrane. A strip-shaped detection line and a quality control line are respectively provided, wherein the end of the nitrocellulose membrane close to the quality control line is abutted against a horizontally arranged strip-shaped water-absorbing pad, and the end of the nitrocellulose membrane close to the detection line Butt against a horizontal strip-shaped colloidal gold pad, and the end of the colloidal gold pad away from the nitrocellulose membrane abuts against a horizontally horizontal strip-shaped sample pad; the colloidal gold pad contains a colloidal gold label pair anti-human thyroglobulin antibody, the detection line is coated with a detection antibody that can specifically bind to the anti-human thyroglobulin antibody, and the quality control line is coated with a detection antibody that can specifically bind to the free anti-human thyroglobulin antibody Quality control antibodies.

The invention relates to a healthcare garment capable of treating cold-coagulation and blood-stasis type dysmenorrhea. The healthcare garment comprises a garment body, a heating device and medicine bags, the heating device comprises a carbon fiber heating wire and heating units, the garment body comprises outer-layer cloth and inner-layer cloth, and positions, corresponding to specific meridians and collaterals of a human body, of the carbon fiber heating wire are arranged between the outer-layer cloth and the inner-layer cloth and connected with the heating unit. The specific meridians and collaterals include foot-yangming stomach meridian, foot-taiyin spleen meridian, foot-taiyang bladder meridian, foot-shaoyin kidney meridian, Ren channel, Du channel and Dai channel; the medicine bags and the heating units are arranged positions, corresponding to human specific acupoints, of the garment body in a one-to-one pairwise manner, and the specific acupoints include Shanzhong, Guanyuan, Ganyu, Guilai, Zhongji, Zusanli, Diji, Sanyinjiao, Ciliao, Taichong and Yongquan acupoints. Corresponding meridians and collaterals and acupoints are heated for the cold-coagulation and blood-stasis typedysmenorrhea, so that pertinence is high. The acupoints and the medicine bags are selected reasonably, and repeated verification shows that the healthcare garment has remarkable treatment effect on the cold-coagulation and blood-stasis type dysmenorrheal.

The invention provides a method for measuring distribution of a human cell drug in an animal body, comprising the following steps of: (1) selecting a PCR(polymerase chain reaction) amplification region according to a human specific gene and designing a PCR amplification primer; (2) extracting human genome DNA(deoxyribonucleic acid), carrying out PCR amplification on a target gene fragment; (3) connecting the amplified fragment with a T vector to construct a standard plasmid; (4) establishing a standard curve by using the standard plasmid; (5) after the human cell drug is applied to an animal, collecting tissues, extracting a total DNA sample to carry out quantitative PCR reaction; and (6) calculating the contents of human genome DNA in the total DNA sample of each tissue by the standard curve, thereby calculating the contents of the human cell drug in the tissues. The measuring method provided by the invention has simple experimental processes and accurate and reliable experimental results.

The invention relates to the antibody engineering medicine and particularly relates to the phage antibody display technology, namely a construction method of a human agkistrodon acutus venom immune ScFv antibody library. The method comprises the following steps of: performing PCR (polymerase chain reaction) amplification by use of human specific IgG light chain and heavy chain primers to obtain PCR products; mixing all PCR products to obtain a light chain PCR mixed product and a heavy chain PCR mixed product respectively; introducing specific primers by taking the light chain PCR mixed product and heavy chain PCR mixed product as templates, and performing PCR amplification to obtain a Linker-VL fragment and a VH-Linker fragment; connecting the obtained Linker-VL fragment and the obtained VH-Linker fragment to obtain a VH-Linker-VL fragment; and importing the obtained VH-Linker-VL fragment into a phage cloning vector to obtain an original library of the human agkistrodon acutus venom immune ScFv antibody library.

The invention provides a human cell specific gene fragment, a specific primer and a probe thereof, and a method for specific quantitative detection of a human gene. According to the invention, throughthe NCBI website and a BLAST sequence comparison function of the NCBI website, a human specific gene fragment with a length of 166 bp on FOXP2 gene is obtained, and human genes in tissues, blood andother non-human samples of various preclinical animals are quantified by qPCR. The human cell specific gene fragment and qPCR quantitative detection method adopted by the invention are high in specificity, strong in sensitivity, good in repeatability and simpler and more convenient to operate, and provide a new thought and a corresponding technical support for quantitative detection of specific human genes.

The invention discloses a specific human gene fragment, a primer and a probe for detecting the specific human gene fragment and application of the specific human gene fragment, and particularly discloses a method comprising the following steps: screening the human specific gene fragment, designing, synthesizing and verifying the specific primer probe, constructing a standard plasma and acquiring the accurate relative molecular mass, drawing a standard curve and finally conducting qPCR (Polymerase Chain Reaction) quantitative detection. Therefore, the most important characteristic of the specific human gene fragment lies in that due to the quite strong specificity of the probe and the primer, a human cell in a sample mixed with other animal sources can be qualitatively and quantitatively detected; a carrier T5 is also known for the first time to be used in the construction of the standard plasma, the time is saved, and the cost is also lowered; and the various steps of a method are optimized, so that the detection is more accurate and sensitive.

Human biliary tree stem / progenitors (hBTSCs) are being used for cell therapies of patients with liver cirrhosis. A cryopreservation method was established to optimize sourcing of hBTSCs for these clinical programs and that comprises serum-free Kubota's Medium (KM) supplemented with 10% dimethyl sulfoxide (DMSO), ˜3% recombinant human albumin and 0.1% hyaluronans. Cryopreserved versus freshly isolated hBTSCs were similar in vitro with respect to self-replication, stemness traits, and multipotency. They were able to differentiate to functional hepatocytes, cholangiocytes or pancreatic islets, yielding similar levels of secretion of albumin or of glucose-inducible levels of insulin. Cryopreserved versus freshly isolated hBTSCs were equally able to engraft into immunocompromised mice yielding cells with human-specific gene expression and human albumin levels in murine serum that were higher for cryopreserved than for freshly isolated hBTSCs. The successful cryoypreservation of hBTSCs facilitates establishment of hBTSCs cell banking offering logistical advantages for clinical programs for treatment of liver disease.

The invention pertains to the field of genetic engineering antibody techniques, in particular to a whole human polypeptide single-chain antibody which has specific affinity for human interleukin 21 designed and expressed by genetic engineering. The engineering antibody polypeptide is formed by joining the light chain and heavy chain variable regions of the antibody end to end with a flexible connecting peptide, wherein, both the framework and complementary determining region of the light chain and heavy chain variable regions are from human. The invention screens out the antibody having specific affinity for human interleukin 21 by a cycle operation of 'gathering-elusion-gathering', and then obtains human specific binding human interleukin 21 through a secretary expression system and an affinity purification system. The antibody of the invention can be applied to coupling to detectable substances and therapeutic agents.